Zoetis (NYSE:ZTS) Given New $200.00 Price Target at Piper Sandler

Zoetis (NYSE:ZTS) had its target price lowered by Piper Sandler from $210.00 to $200.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other research analysts have also recently issued reports about the company. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Morgan Stanley dropped their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $214.00.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $173.99 on Monday. The stock has a 50 day moving average price of $169.11 and a 200 day moving average price of $179.11. Zoetis has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $78.50 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.15%. Zoetis’s payout ratio is 37.59%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Zoetis

A number of large investors have recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.